Follow-on Offering

Healthcare
Follow-on Offering

Summary

Baird served as sole underwriter in this transaction

About

NanoString Technologies, Inc. (“NanoString” or the “Company”) (NASDAQ: NSTG) recently completed a follow-on offering of 3,450,000 shares of common stock at a price of $16.75 per share, generating gross proceeds of approximately $57.8 million. The Company intends to use the net proceeds of this offering for general corporate purposes and working capital.

NanoString provides life science tools for translational research and molecular diagnostic products. The Company’s nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The Company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the Company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology. NanoString is based in Seattle, Washington.
CONTACT US TO LEARN MORE
Healthcare
Follow-on Offering
Date
June 2017
Company
NanoString Technologies, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share